← Back to Clinical Trials
Recruiting NCT07552415

NCT07552415 Does Joint Immobilization Following Revision Total Knee Arthroplasty Improve Range of Motion Following Surgery?

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07552415
Status Recruiting
Phase
Sponsor Hospital for Special Surgery, New York
Condition Aseptic Revision Knee Arthroplasty
Study Type INTERVENTIONAL
Enrollment 170 participants
Start Date 2026-04
Primary Completion 2027-01

Trial Parameters

Condition Aseptic Revision Knee Arthroplasty
Sponsor Hospital for Special Surgery, New York
Study Type INTERVENTIONAL
Phase N/A
Enrollment 170
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2026-04
Completion 2027-01
Interventions
Knee immobilizerNo Knee Immobilizer

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this study is to evaluate if knee immobilization for 10 days following revision total knee arthroplasty (rTKA) improves knee joint range of motion at 3 months postoperatively compared to standard of care postoperative protocol. Participants will be assigned to one of two groups. One group will wear a knee brace that keeps the knee straight for 10 days after surgery and will not perform knee range of motion exercises during that time. The other group will not wear a brace and will follow the standard physical therapy program, including knee range of motion exercises, starting after surgery.

Eligibility Criteria

Inclusion Criteria: * Patients undergoing revision TKA for aseptic indications including aseptic loosening, polyethylene wear, instability, malalignment, periprosthetic fracture. * Patients undergoing revision TKA of one or both components. Exclusion Criteria: * Patients who are undergoing revision TKA for stiffness. * Patients with occult infection not recognized prior to revision. * Patients with hinged TKA component reconstructions. * Patients undergoing revision for liner exchange. * History of VTE/PE. * Patients on pre-operative anticoagulation. * BMI ≥ 40. * Patients with preoperative opioid use equal to or exceeding 150 Morphine Milligram Equivalents (MMEs)/day within 90 days of revision TKA.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology